Baricitinib/tofacitinib: Inefficacy, treatment failure and digestive adverse effects: 4 case reports.

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In an observational, single-centre and retrospective study including patients receiving Janus kinase inhibitors (JAKi) for RA in the Rheumatology department of Amiens University Hospital between 1 October 2017 and 20 May 2020, four patients [ I ages and sexes not stated i ] were described, who exhibited inefficacy, treatment failure or developed digestive adverse effects during treatment with baricitinib and tofacitinib for rheumatoid arthritis (RA). The remaining one patient exhibited baricitinib treatment failure, whose tofacitinib treatment was continued until the data collection [ I duration of treatment to reaction onset not stated i ]. [Extracted from the article]